Get the Stockscreener App
0.5931
8.89%
0.0484
After Hours:
.60
0.0069
+1.16%
Applied Therapeutics Inc stock is traded at $0.5931, with a volume of 3.20M.
It is up +8.89% in the last 24 hours and down -27.23% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.5447
Open:
$0.5489
24h Volume:
3.20M
Relative Volume:
0.50
Market Cap:
$69.01M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.4393
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-2.72%
1M Performance:
-27.23%
6M Performance:
-88.09%
1Y Performance:
-80.03%
1-Day Range:
$0.5489
$0.625
1-Week Range:
$0.5447
$0.68
52-Week Range:
$0.5447
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.5931 | 69.01M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
APLT INVESTOR ALERT: Kirby McInerney LLP Notifies Applied - GlobeNewswire
APLT INVESTOR ALERT: Kirby McInerney LLP Notifies Applied Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire Inc.
Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineAPLT - Stockhouse Publishing
2025-01-30 | APLT COURT NEWS: Applied Therapeutics has been Sued for FraudContact BFA Law before February 18 Class Action Deadline if You Suffered Losses | NDAQ:APLT | Press Release - Stockhouse Publishing
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - cnhinews.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
2025-01-29 | Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT | NDAQ:APLT | Press Release - Stockhouse Publishing
APLT Deadline Approaching on February 18, 2025: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Class Action Lawsuit Deadline - PR Newswire
DEADLINE ALERT for MGPI, APLT, and KSPI: The Law Offices of - GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics - GlobeNewswire
2025-01-29 | Investors who lost money on Applied Therapeutics, Inc.(APLT) should contact Levi & Korsinsky about pending Class ActionAPLT | NDAQ:APLT | Press Release - Stockhouse Publishing
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
APLT Lead Plaintiff Deadline ApproachingContact Robbins LLP for Information About the Pending Class Action Against Applied Therapeutics, Inc. - PR Newswire
2025-01-28 | Levi & Korsinsky Reminds Applied Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025APLT | NDAQ:APLT | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesAPLT - PR Newswire
APLT Investors Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
APLT SHAREHOLDER NEWS: Applied Therapeutics Investors are - GlobeNewswire
Deadline Alert: Applied Therapeutics, Inc. (APLT) Investors - GlobeNewswire
APLT stock touches 52-week low at $0.6 amid market challenges By Investing.com - Investing.com South Africa
Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing
Lead Plaintiff Deadline Approaching in APLT: Kessler Topaz - GlobeNewswire
APLT stock touches 52-week low at $0.6 amid market challenges - MSN
Franklin Resources Inc. Reduces Stake in Applied Therapeutics Inc. - GuruFocus.com
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure - The Bakersfield Californian
Applied Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your RightsAPLT - The Malaysian Reserve
APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
APLT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. (APLT) - StreetInsider.com
APLT ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Applied Therapeutics, Inc. (APLT) - Marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure - The Bakersfield Californian
APLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Applied Therapeutics, Inc. - PR Newswire
APLT CLASS ACTION DEADLINE: Applied Therapeutics, Inc. - GlobeNewswire
APLT Investors Have Opportunity to Lead Applied Therapeutics, In - GuruFocus.com
2025-01-22 | APLT CLASS ACTION NOTICE: Lose Money on Your Applied Therapeutics Investment? You may have been affected by FraudContact BFA Law | NDAQ:APLT | Press Release - Stockhouse Publishing
Deadline Alert: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged To Contact - The Bakersfield Californian
Investors who lost money on Applied Therapeutics, Inc.(APLT) should contact Levi & Korsinsky about pending - EIN News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics - GlobeNewswire
Applied Therapeutics, Inc. (APLT) Investors: February 18, - GlobeNewswire
Hennion & Walsh Asset Management Inc. Raises Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat
APLT DEADLINE NOTICE: Applied Therapeutics Investors are - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
APLT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Applied Therapeutics, Inc. (APLT) Investors: February 18, 2025 Filing Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Applied Therapeutics, Inc. - GlobeNewswire
2025-01-21 | Levi & Korsinsky Notifies Shareholders of Applied Therapeutics, Inc.(APLT) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:APLT | Press Release - Stockhouse Publishing
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality - The Manila Times
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) - GuruFocus.com
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):